| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
NEUROLOGY 1996;47: 889-894
Address correspondence and reprint requests to Dr. W.A. Sibley, University Hospital, Tucson, AZ 85724.
This article has been cited by other articles:
|
|
 |
|
  A. R. Pachner, J. D. Warth, A. Pace, S. Goelz, and On behalf of the INSIGHT investigators Effect of neutralizing antibodies on biomarker responses to interferon beta: The INSIGHT study Neurology, November 3, 2009; 73(18): 1493 - 1500. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N Koch-Henriksen, P. Sorensen, K Bendtzen, and E. Flachs The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis Multiple Sclerosis, May 1, 2009; 15(5): 601 - 605. [Abstract] [PDF]
|
|
|
|
 |
|
 P. Soelberg Sorensen Review: Neutralizing antibodies against interferon-beta Therapeutic Advances in Neurological Disorders, September 1, 2008; 1(2): 125 - 141. [Abstract] [PDF]
|
|
|
|
|
|
P. Sorensen, N Koch-Henriksen, E. Flachs, and K Bendtzen Is the treatment effect of IFN-{beta} restored after the disappearance of neutralizing antibodies? Multiple Sclerosis, July 1, 2008; 14(6): 837 - 842. [Abstract] [PDF]
|
|
|
|
|
|
S. Malucchi, F. Gilli, M. Caldano, F. Marnetto, P. Valentino, L. Granieri, A. Sala, M. Capobianco, and A. Bertolotto Predictive markers for response to interferon therapy in patients with multiple sclerosis Neurology, March 25, 2008; 70(13_Part_2): 1119 - 1127. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Farrell, R. Kapoor, S. Leary, P. Rudge, A. Thompson, D. Miller, and G. Giovannoni Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of Interferon-beta Multiple Sclerosis, March 1, 2008; 14(2): 212 - 218. [Abstract] [PDF]
|
|
|
|
 |
|
 A Sominanda, J Hillert, and A Fogdell-Hahn In vivo bioactivity of interferon-beta in multiple sclerosis patients with neutralising antibodies is titre-dependent J. Neurol. Neurosurg. Psychiatry, January 1, 2008; 79(1): 57 - 62. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Boz, J. Oger, E. Gibbs, S.E. Grossberg, and the Neurologists of the UBC MS Clinic Reduced effectiveness of long-term interferon-{beta} treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study Multiple Sclerosis, November 1, 2007; 13(9): 1127 - 1137. [Abstract] [PDF]
|
|
|
|
|
|
P. A. Calabresi, G. Giovannoni, C. Confavreux, S. L. Galetta, E. Havrdova, M. Hutchinson, L. Kappos, D. H. Miller, P. W. O'Connor, J. T. Phillips, et al. The incidence and significance of anti-natalizumab antibodies: Results from AFFIRM and SENTINEL Neurology, October 2, 2007; 69(14): 1391 - 1403. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Noronha Neutralizing antibodies to interferon Neurology, June 12, 2007; 68(24_suppl_4): S16 - S22. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Sorensen, N. Koch-Henriksen, and K. Bendtzen Are ex vivo neutralising antibodies against IFN-{beta} always detrimental to therapeutic efficacy in multiple sclerosis? Multiple Sclerosis, June 1, 2007; 13(5): 616 - 621. [Abstract] [PDF]
|
|
|
|
|
|
R. A Farrell and G. Giovannoni Measuring and management of Anti-Interferon Beta Antibodies in subjects with Multiple Sclerosis Multiple Sclerosis, June 1, 2007; 13(5): 567 - 577. [Abstract] [PDF]
|
|
|
|
|
|
J. Oger Neutralizing antibodies and interferon treatment of multiple sclerosis: addressing the open questions Multiple Sclerosis, May 1, 2007; 13(1_suppl): 5 - 7. [PDF]
|
|
|
|
|
|
A. AL-Sabbagh Neutralizing antibodies in MS therapy: reviewing the Rebif experience Multiple Sclerosis, May 1, 2007; 13(1_suppl): 8 - 13. [Abstract] [PDF]
|
|
|
|
|
|
S. E. Goelz and L. Walt Development of neutralizing antibodies to intramuscular interferon beta-1a (Avonex (R)) Multiple Sclerosis, May 1, 2007; 13(1_suppl): 14 - 20. [Abstract] [PDF]
|
|
|
|
|
|
F. Blanchette Clinical significance of glatiramer acetate antibodies Multiple Sclerosis, May 1, 2007; 13(1_suppl): 28 - 35. [Abstract] [PDF]
|
|
|
|
|
|
J. Oger and E. Gibbs Binding antibodies: Vancouver's perspective Multiple Sclerosis, May 1, 2007; 13(1_suppl): 36 - 43. [Abstract] [PDF]
|
|
|
|
|
|
A.T. Reder Neutralizing antibodies in multiple sclerosis: a complex impact on interferon responses, magnetic resonance imaging findings and clinical outcomes Multiple Sclerosis, May 1, 2007; 13(1_suppl): 53 - 62. [Abstract] [PDF]
|
|
|
|
|
|
D. S. Goodin, E. M. Frohman, B. Hurwitz, P. W. O'Connor, J. J. Oger, A. T. Reder, and J. C. Stevens Neutralizing antibodies to interferon beta: Assessment of their clinical and radiographic impact: An evidence report: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology Neurology, March 27, 2007; 68(13): 977 - 984. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Sominanda, U Rot, M Suoniemi, F Deisenhammer, J Hillert, and A Fogdell-Hahn Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity Multiple Sclerosis, March 1, 2007; 13(2): 208 - 214. [Abstract] [PDF]
|
|
|
|
|
|
C Gneiss, P Tripp, F Reichartseder, R Egg, R Ehling, A Lutterotti, M Khalil, B Kuenz, I Mayringer, M Reindl, et al. Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients Multiple Sclerosis, November 1, 2006; 12(6): 731 - 737. [Abstract] [PDF]
|
|
|
|
|
|
B. Petersen, K. Bendtzen, N. Koch-Henriksen, M. Ravnborg, C. Ross, P. S. Sorensen, and The Danish Multiple Sclerosis Group Persistence of neutralizing antibodies after discontinuation of IFN{beta} therapy in patients with relapsing-remitting multiple sclerosis Multiple Sclerosis, June 1, 2006; 12(3): 247 - 252. [Abstract] [PDF]
|
|
|
|
 |
|
 S. J. Pittock, B. G. Weinshenker, J. H. Noseworthy, C. F. Lucchinetti, M. Keegan, D. M. Wingerchuk, J. Carter, E. Shuster, and M. Rodriguez Not every patient with multiple sclerosis should be treated at time of diagnosis. Arch Neurol, April 1, 2006; 63(4): 611 - 614. [Full Text] [PDF]
|
|
|
|
|
|
C Ross, K M Clemmesen, P S Sorensen, N Koch-Henriksen, and K Bendtzen Measuring and evaluating interferon b-induced antibodies in patients with multiple sclerosis Multiple Sclerosis, February 1, 2006; 12(1): 39 - 46. [Abstract] [PDF]
|
|
|
|
|
|
D R Smith, B Weinstock-Guttman, J A Cohen, X Wei, C Gutmann, R Bakshi, M Olek, L Stone, S Greenberg, D Stuart, et al. A randomized blinded trial of combination therapy with cyclophosphamide in patients with active multiple sclerosis on interferon beta Multiple Sclerosis, October 1, 2005; 11(5): 573 - 582. [Abstract] [PDF]
|
|
|
|
|
|
R. M Herndon, R. A Rudick, F. E Munschauer III, M. K Mass, A. M Salazar, M. E Coats, R. Labutta, J. R Richert, S. L Cohan, C. Genain, et al. Eight-year immunogenicity and safety of interferon beta-1a-Avonex(R)treatment in patients with multiple sclerosis Multiple Sclerosis, August 1, 2005; 11(4): 409 - 419. [Abstract] [PDF]
|
|
|
|
|
|
G. Giovannoni and A. Goodman Neutralizing anti-IFN-{beta} antibodies: How much more evidence do we need to use them in practice? Neurology, July 12, 2005; 65(1): 6 - 8. [Full Text] [PDF]
|
|
|
|
|
|
L. Kappos, M. Clanet, M. Sandberg-Wollheim, E. W. Radue, H. P. Hartung, R. Hohlfeld, J. Xu, D. Bennett, A. Sandrock, S. Goelz, et al. Neutralizing antibodies and efficacy of interferon {beta}-1a: A 4-year controlled study Neurology, July 12, 2005; 65(1): 40 - 47. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. S. Francis, G. P.A. Rice, J. C. Alsop, and for the PRISMS (Prevention of Relapses and Disabil Interferon {beta}-1a in MS: Results following development of neutralizing antibodies in PRISMS Neurology, July 12, 2005; 65(1): 48 - 55. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. S. Sorensen, N. Koch-Henriksen, C. Ross, K. M. Clemmesen, K. Bendtzen, and the Danish Multiple Sclerosis Study Group Appearance and disappearance of neutralizing antibodies during interferon-beta therapy Neurology, July 12, 2005; 65(1): 33 - 39. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Saida, K. Tashiro, Y. Itoyama, T. Sato, Y. Ohashi, Z. Zhao, and the Interferon Beta-1b Multiple Sclerosis Study Gr Interferon beta-1b is effective in Japanese RRMS patients: A randomized, multicenter study Neurology, February 22, 2005; 64(4): 621 - 630. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. H. Stuart, S. Cohan, J. R. Richert, and A. Achiron Selecting a disease-modifying agent as platform therapy in the long-term management of multiple sclerosis Neurology, December 14, 2004; 63(11_suppl_5): S19 - S27. [Abstract] [Full Text]
|
|
|
|
|
|
T. K. Vartanian, S. S. Zamvil, E. Fox, and P. S. Sorensen Neutralizing antibodies to disease-modifying agents in the treatment of multiple sclerosis Neurology, December 14, 2004; 63(11_suppl_5): S42 - S49. [Abstract] [Full Text]
|
|
|
|
|
|
A J Petkau, G C Ebers, and A T Reder Letter to the editor Multiple Sclerosis, December 1, 2004; 10(6): 715 - 715. [PDF]
|
|
|
|
|
|
C Gneiss, M Reindl, A Lutterotti, R Ehling, R Egg, M Khalil, T Berger, and F Deisenhammer Interferon-beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativity Multiple Sclerosis, October 1, 2004; 10(5): 507 - 510. [Abstract] [PDF]
|
|
|
|
|
|
T L Vollmer, J T Phillips, A D Goodman, M A Agius, M A Libonati, J L Giacchino, and J S Grundy An open-label safety and drug interaction study of natalizumab (AntegrenTM) in combination with interferon-beta (Avonex(R)) in patients with multiple sclerosis Multiple Sclerosis, October 1, 2004; 10(5): 511 - 520. [Abstract] [PDF]
|
|
|
|
|
|
G Giovannoni Is it time to consider rationalising IFN-{beta} treatment in individuals with multiple sclerosis? J. Neurol. Neurosurg. Psychiatry, September 1, 2004; 75(9): 1234 - 1234. [Full Text] [PDF]
|
|
|
|
|
|
A Bertolotto, A Sala, S Malucchi, F Marnetto, M Caldano, A Di Sapio, M Capobianco, and F Gilli Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies J. Neurol. Neurosurg. Psychiatry, September 1, 2004; 75(9): 1294 - 1299. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Malucchi, A. Sala, F. Gilli, R. Bottero, A. Di Sapio, M. Capobianco, and A. Bertolotto Neutralizing antibodies reduce the efficacy of {beta}IFN during treatment of multiple sclerosis Neurology, June 8, 2004; 62(11): 2031 - 2037. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Rudge Interferon antibodies: do they alter the beneficial effects of beta-interferon upon relapse rate in multiple sclerosis? Multiple Sclerosis, April 1, 2004; 10(2): 123 - 125. [PDF]
|
|
|
|
|
|
A J. Petkau, R. A White, G. C Ebers, A. T Reder, W. A Sibley, F. D Lublin, D. W Paty, and IFNB Multiple Sclerosis Study Group Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis Multiple Sclerosis, April 1, 2004; 10(2): 126 - 138. [Abstract] [PDF]
|
|
|
|
|
|
M Clanet, L Kappos, H-P Hartung, R Hohlfeld, and The European IFNss-1a Dose-Comparison Study Invest Interferon {beta}-1a in relapsing multiple sclerosis: four-year extension of the European IFN{beta}-1a Dose-C omparison Study Multiple Sclerosis, April 1, 2004; 10(2): 139 - 144. [Abstract] [PDF]
|
|
|
|
|
|
J. A. Frank, N. Richert, C. Bash, L. Stone, P. A. Calabresi, B. Lewis, R. Stone, T. Howard, and H. F. McFarland Interferon-{beta}-1b slows progression of atrophy in RRMS: Three-year follow-up in NAb- and NAb+ patients Neurology, March 9, 2004; 62(5): 719 - 725. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Gilli, A. Bertolotto, A. Sala, F. Hoffmann, M. Capobianco, S. Malucchi, T. Glass, L. Kappos, R. L.P. Lindberg, and D. Leppert Neutralizing antibodies against IFN-{beta} in multiple sclerosis: antagonization of IFN-{beta} mediated suppression of MMPs Brain, February 1, 2004; 127(2): 259 - 268. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. H. Salama, J. Hong, Y. C. Q. Zang, A. El-Mongui, and J. Zhang Blocking effects of serum reactive antibodies induced by glatiramer acetate treatment in multiple sclerosis Brain, December 1, 2003; 126(12): 2638 - 2647. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Bendtzen Anti-IFN BAb and NAb antibodies: A minireview Neurology, November 11, 2003; 61(90095): S6 - 10. [Full Text]
|
|
|
|
|
|
G. Giovannoni Strategies to treat and prevent the development of neutralizing anti-interferon-{beta} antibodies Neurology, November 11, 2003; 61(90095): S13 - 17. [Abstract] [Full Text]
|
|
|
|
|
|
P. S. Sorensen Antibodies to IFN-beta: The Danish National IFN-beta Project Neurology, November 11, 2003; 61(90095): S27 - 28. [Full Text]
|
|
|
|
|
|
M. Kremenchutzky Long-term evolution of anti-INF{beta} antibodies in IFN{beta}-treated MS patients: The London, Canada, MS Clinic experience Neurology, November 11, 2003; 61(90095): S29 - 30. [Full Text]
|
|
|
|
|
|
A. J. Petkau Statistical approaches to assessing the effects of neutralizing antibodies: IFN{beta}-1b in the pivotal trial of relapsing-remitting multiple sclerosis Neurology, November 11, 2003; 61(90095): S35 - 37. [Abstract] [Full Text]
|
|
|
|
|
|
N Lawrence, J Oger, T Aziz, J Palace, and A Vincent A sensitive radioimmunoprecipitation assay for assessing the clinical relevance of antibodies to IFN {beta} J. Neurol. Neurosurg. Psychiatry, September 1, 2003; 74(9): 1236 - 1239. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Casoni, E. Merelli, R. Bedin, A. Martella, A. Cesinaro, and A. Bertolotto Necrotizing skin lesions and NA Bs development in a multiple sclerosis patient treated with IFN{beta} 1b Multiple Sclerosis, August 1, 2003; 9(4): 420 - 423. [Abstract] [PDF]
|
|
|
|
|
|
C Ortenzi, G Giovannoni, F Deisenhammer, and F E Munschauer Neutralising antibodies to interferon {beta} J. Neurol. Neurosurg. Psychiatry, August 1, 2003; 74(8): 1162 - 1163. [Full Text] [PDF]
|
|
|
|
|
|
A. Bertolotto, F. Gilli, A. Sala, M. Capobianco, S. Malucchi, E. Milano, F. Melis, F. Marnetto, R. L.P. Lindberg, R. Bottero, et al. Persistent neutralizing antibodies abolish the interferon {beta} bioavailability in MS patients Neurology, February 25, 2003; 60(4): 634 - 639. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Kob, J Harvey, F Schautzer, S Kascha, D Bibl, R Egg, M Reindl, T Berger, and F Deisenhammer A novel and rapid assay for the detection of neutralizing antibodies against interferon-beta Multiple Sclerosis, February 1, 2003; 9(1): 32 - 35. [Abstract] [PDF]
|
|
|
|
|
|
C. Polman, L. Kappos, R. White, F. Dahlke, K. Beckmann, C. Pozzilli, A. Thompson, J. Petkau, and D. Miller Neutralizing antibodies during treatment of secondary progressive MS with interferon {beta}-1b Neurology, January 14, 2003; 60(1): 37 - 43. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Scagnolari, M. Casato, F. Bellomi, F. De Pisa, O. Turriziani, R. Coviello, M. R. Pirro, F. Dianzani, and G. Antonelli Serum Interferon (IFN)-Neutralizing Antibodies and Bioactivities of IFNs in Patients with Severe Type II Essential Mixed Cryoglobulinemia Clin. Vaccine Immunol., January 1, 2003; 10(1): 70 - 77. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Burks, B. G. Arnason, P. K. Coyle, C. C. Ford, A. Noronha, and K. W. Rammohan Issues and Practices in Multiple Sclerosis Neurorehabil Neural Repair, December 1, 2002; 16(4): 307 - 320. [Abstract] [PDF]
|
|
|
|
 |
|
 S. A. Brod Ingested Type I Interferon: State of the Art as Treatment for Autoimmunity Experimental Biology and Medicine, December 1, 2002; 227(11): 981 - 988. [Abstract] [Full Text]
|
|
|
|
|
|
G Giovannoni, F E Munschauer 3rd, and F Deisenhammer Neutralising antibodies to interferon beta during the treatment of multiple sclerosis J. Neurol. Neurosurg. Psychiatry, November 1, 2002; 73(5): 465 - 469. [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Galetta, C. Markowitz, and A. G. Lee Immunomodulatory Agents for the Treatment of Relapsing Multiple Sclerosis: A Systematic Review Arch Intern Med, October 28, 2002; 162(19): 2161 - 2169. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Bertolotto, S Malucchi, A Sala, G Orefice, P B Carrieri, M Capobianco, E Milano, F Melis, and M T Giordana Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory J. Neurol. Neurosurg. Psychiatry, August 1, 2002; 73(2): 148 - 153. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A J Coles Neutralising antibodies to the beta interferons J. Neurol. Neurosurg. Psychiatry, August 1, 2002; 73(2): 110 - 111. [Full Text]
|
|
|
|
|
|
A.-M. Vallittu, M. Halminen, J. Peltoniemi, J. Ilonen, I. Julkunen, A. Salmi, J.-P. Eralinna, and the Finnish Beta-Interferon Study Group Neutralizing antibodies reduce MxA protein induction in interferon- beta-1a-treated MS patients Neurology, June 25, 2002; 58(12): 1786 - 1790. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Bashir and J. N. Whitaker Current Immunotherapy for Demyelinating Diseases Arch Neurol, May 1, 2002; 59(5): 726 - 731. [Full Text] [PDF]
|
|
|
|
|
|
P. A. Calabresi Considerations in the treatment of relapsing-remitting multiple sclerosis Neurology, April 23, 2002; 58(90084): S10 - 22. [Abstract] [Full Text]
|
|
|
|
|
|
S. D. Cook, J. R. Quinless, A. Jotkowitz, and P. Beaton Serum IFN neutralizing antibodies and neopterin levels in a cross-section of MS patients Neurology, September 25, 2001; 57(6): 1080 - 1084. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Rice The Significance of Neutralizing Antibodies in Patients With Multiple Sclerosis Treated With Interferon Beta Arch Neurol, August 1, 2001; 58(8): 1297 - 1298. [Full Text] [PDF]
|
|
|
|
|
|
Y. C. Q. Zang, D. Yang, J. Hong, M. V. Tejada-Simon, V. M. Rivera, and J. Z. Zhang Immunoregulation and blocking antibodies induced by interferon beta treatment in MS Neurology, August 8, 2000; 55(3): 397 - 404. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Deisenhammer, I. Mayringer, J. Harvey, E. Dilitz, T. Gasse, D. Stadlbauer, M. Reindl, and T. Berger A comparative study of the relative bioavailability of different interferon beta preparations Neurology, June 13, 2000; 54(11): 2055 - 2060. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. U. Walther and R. Hohlfeld Multiple sclerosis: Side effects of interferon beta therapy and their management Neurology, November 1, 1999; 53(8): 1622 - 1622. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Rudick Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis and Future Directions for Multiple Sclerosis Therapeutics Arch Neurol, September 1, 1999; 56(9): 1079 - 1084. [Full Text] [PDF]
|
|
|
|
|
|
P. F Smith and C. L Darlington Recent developments in drug therapy for multiple sclerosis Multiple Sclerosis, April 1, 1999; 5(2): 110 - 120. [Abstract] [PDF]
|
|
|
|
|
|
F. Deisenhammer, M. Reindl, J. Harvey, T. Gasse, E. Dilitz, and T. Berger Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies Neurology, April 1, 1999; 52(6): 1239 - 1239. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. P. A. Rice, B. Paszner, J. Oger, J. Lesaux, D. Paty, and G. Ebers The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon {beta}-1b Neurology, April 1, 1999; 52(6): 1277 - 1277. [Abstract] [Full Text]
|
|
|
|
|
|
K. M. Myhr, T. Riise, F. E. G. Lilleas, T. G. Beiske, E. G. Celius, A. Edland, D. Jensen, J. P. Larsen, R. Nilsen, M. W. Nortvedt, et al. Interferon-{alpha}2a reduces MRI disease activity in relapsing-remitting multiple sclerosis Neurology, March 1, 1999; 52(5): 1049 - 1049. [Abstract] [Full Text]
|
|
|
|
|
|
R. M. Herndon and L. Jacobs Interferons Should Be Used to Treat Most Patients With MS Arch Neurol, December 1, 1998; 55(12): 1581 - 1583. [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Rudick A 29-Year-Old Man With Multiple Sclerosis JAMA, October 28, 1998; 280(16): 1432 - 1439. [Full Text] [PDF]
|
|
|
|
|
|
G Martino, R Furlan, F Galbiati, P L Poliani, A Bergami, L M. Grimaldi, L Adorini, and G Comi A gene therapy approach to treat demyelinating diseases using nonreplicative herpetic vectors engineered to produce cytokines Multiple Sclerosis, June 1, 1998; 4(3): 222 - 227. [Abstract] [PDF]
|
|
|
|
|
|
O A Khan, H Jiang, P S Subramaniam, H M Johnson, and S S Dhib-Jalbut Immunomodulating functions of recombinant ovine interferon tau: potential for therapy in mulitple sclerosis and autoimmune disorders Multiple Sclerosis, April 1, 1998; 4(2): 63 - 69. [Abstract] [PDF]
|
|
|
|
 |
|
 R. A. Rudick, J. A. Cohen, B. Weinstock-Guttman, R. P. Kinkel, and R. M. Ransohoff Management of Multiple Sclerosis N. Engl. J. Med., November 27, 1997; 337(22): 1604 - 1611. [Full Text] [PDF]
|
|
|
|
|
|
P. Kivisakk, G. Alm, W. Tian, D. Matusevicius, S. Fredrikson, and H. Link Neutralising and binding anti-interferon-{beta}-1 b (IFN-b-1 b) antibodies during IFN-{beta}-1 b treatment of multiple sclerosis Multiple Sclerosis, June 1, 1997; 3(3): 184 - 190. [Abstract] [PDF]
|
|
|
|
|
|
S. A Brod, R. H Kerman, L. D Nelson, G. D Marshall JR, E. M Henninger, M. Khan, R. Jin, and J. S Wolinsky Ingested IFN-{alpha} has biological effects in humans with relapsing-remitting multiple sclerosis Multiple Sclerosis, February 1, 1997; 3(1): 1 - 7. [Abstract] [PDF]
|
|
|
|
|
|
J. Halper The Psychoeducational Approach to Complex Protocols in Neurorehabilitation Neurorehabil Neural Repair, January 1, 1997; 11(3): 149 - 154. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
